Molecular modelling of the androgen receptor axis: Rational basis for androgen receptor intervention in androgen-independent prostate cancer

BJU International, Supplement

Volumn 96, Issue 2, 2005, Pages 2-9

  Fletterick, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Androgen receptor coregulators; Androgen independent prostate cancer; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; REGULATOR PROTEIN; REPRESSOR PROTEIN;

CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CRYSTALLOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; HIGH THROUGHPUT SCREENING; MOLECULAR MODEL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ANALYSIS;

ANDROGEN ANTAGONISTS; ANDROGENS; DRUG DESIGN; HUMANS; MALE; MODELS, MOLECULAR; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 29944446162     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05940.x     Document Type: Conference Paper

References (27)

1. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989; 15: 233-50
2. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 331: 996-1004
3. Visakorpi T, Hyytinene E, Koivisto P et al. In vivo amplification of theandrogen receptor gene and progression of human prostate cancer. Nature Genet 1995; 9: 401-6
4. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TLJ, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-5
5. Linja MJ, Porkka KP, Kang Z et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10: 1032-40
6. Taplin ME, Balk SP. Androgen receptor, a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90
7. Yuan X, Lu ML, Li T, Balk SP. SRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem 2001; 276: 46647-54
8. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989; 245: 371-8
9. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266: 510-8
10. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 2002; 16: 1492-501
11. 2-terminal conserved motif interacts with the COOH terminus of Hsp70-interacting protein (CHIP). J Biol Chem 2004; 279: 30643-53
12. Chen D, Ma H, Hong H et al. Regulation of transcription by a protein methyltransferase. Science 1999; 284: 2174-7
13. Miyoshi Y, Ishiguro H, Uemura H et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostote 2003; 56: 280-6
14. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 1998; 393: 392-6
15. Shiau AK, Barstad D, Loria PM et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-37
16. Brzozowski AM, Pike ACW, Dauter Z et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-8
17. Greschik H, Flaig R, Renaud J-P, Moras D. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem 2004; 279: 33639-46
18. Xu HE, Stanley TB, Montana VG et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature 2002; 415: 813-7
19. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997; 387: 733-6
20. Miyamoto H, Rahman M, Takatera H et al. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002; 277: 4609-17
21. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004; 19: 3-12
22. Hu Y-C, Yeh S, Yeh S-D et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 2004; 279: 33438-46
23. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 2003; 278: 19619-26
24. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. PNAS 2003; 100: 5124-9
25. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277: 26321-6
26. Elhaji YA, Wu JH, Gottlieb B et al. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes. Mol Endocrinol 2004; 18: 1876-86
27. Baxter JD, Goede P, Apriletti JW et al. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 2002; 143: 517-24